15 active trials 13 recruiting 7 Phase 3 4 disease areas 12 changes in 30 days
5 trials changed in the last 30 days: 0 stopped, 1 with a notable change, 4 with minor changes only.
Primary completion pushed from May 15, 2027 to Sep 30, 2028
Also in this update: Primary endpoint(s) modified; Completion pushed from Jul 15, 2027 to Mar 30, 2030
Revolution Medicines, Inc.Phase 1/2 NCT06445062 Registry history of NCT06445062 on ClinicalTrials.gov (opens the registry)
Updated
Trial sites expanded: 61 → 82 locations
And 2 more changes in the last 30 days
Revolution Medicines, Inc.Phase 3 NCT07491445 Registry history of NCT07491445 on ClinicalTrials.gov (opens the registry)
Updated
Trial sites expanded: 153 → 158 locations
Revolution Medicines, Inc.Phase 3 NCT06881784 Registry history of NCT06881784 on ClinicalTrials.gov (opens the registry)
Updated
Trial sites expanded: 9 → 13 locations
Revolution Medicines, Inc.Phase 3 NCT07621718 Registry history of NCT07621718 on ClinicalTrials.gov (opens the registry)
Updated
Trial sites expanded: 74 → 78 locations
And 1 more change in the last 30 days
Revolution Medicines, Inc.Phase 3 NCT07252232 Registry history of NCT07252232 on ClinicalTrials.gov (opens the registry)
Updated
| Phase 1 | 3 | |
| Phase 1/2 | 5 | |
| Phase 3 | 7 |
| NCT ID | Title | Condition | Status | Updated |
|---|---|---|---|---|
| Phase 3 | ||||
| NCT07491445 | Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With… | Pancreatic Cancer | Recruiting | 2026-10-02 |
| NCT06881784 | Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301) | NSCLC (Non-small Cell Lung Cancer) | Recruiting | 2026-09-29 |
| NCT07621718 | Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of… | Pancreatic Cancer | Recruiting | 2026-09-28 |
| NCT07252232 | Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal… | Pancreatic Cancer | Recruiting | 2026-09-23 |
| NCT07805954 | Study of Zoldonrasib (RMC-9805) Plus Daraxonrasib (RMC-6236) Versus Gemcitabine and… | Pancreatic Cancer | Recruiting | 2026-09-08 |
| NCT07777822 | Study of Pembrolizumab + Pemetrexed + Platinum Chemotherapy With or Without Zoldonrasib… | NSCLC | Recruiting | 2026-08-20 |
| NCT06625320 | Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic… | Pancreatic Cancer | Active, Not Recruiting | 2026-06-02 |
| Phase 1/2 | ||||
| NCT06128551 | Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in… | Non-Small Cell Lung Cancer (NSCLC) | Recruiting | 2026-09-22 |
| NCT06445062 | Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors | Colorectal Cancer | Recruiting | 2026-09-22 |
| NCT07397338 | Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors | Advanced Solid Tumors | Recruiting | 2026-08-03 |
| NCT06162221 | Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC | Non-Small Cell Lung Cancer, NSCLC | Recruiting | 2026-06-30 |
| NCT05379985 | Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in… | Non-small Cell Lung Cancer (NSCLC) | Recruiting | 2026-05-15 |
| Phase 1 | ||||
| NCT07349537 | Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors | Non-small Cell Lung Cancer (NSCLC) | Recruiting | 2026-09-17 |
| NCT06040541 | Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors | Non-small Cell Lung Cancer (NSCLC) | Recruiting | 2026-06-03 |
| NCT05462717 | Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With… | Non-Small Cell Lung Cancer (NSCLC) | Active, Not Recruiting | 2026-05-15 |
Pancreatic Cancer (11) · Lung Cancer (9) · Non-Small Cell Lung Cancer (NSCLC) (9) · Colorectal Cancer (7)